EU Approves Galderma’s NEMLUVIO for Atopic Dermatitis and Prurigo Nodularis
Galderma has announced that the European Commission has approved NEMLUVIO in the European Union (EU) to treat both moderate-to-severe atopic dermatitis and prurigo nodularis. The approval allows Nemluvio to be used subcutaneously for patients aged 12 and older with moderate-to-severe atopic dermatitis who require systemic therapy, as well as for adults with moderate-to-severe prurigo nodularis who are eligible for systemic treatment.
NEMLUVIO is the first approved monoclonal antibody specifically targeting IL-31 receptor alpha, blocking IL-31 signaling. IL-31 is a neuroimmune cytokine th...
